Biogen (BIIB) CEO says LEQEMBI IQLIK is eligible for part D reimbursement, but won't be fully reimbursed until January 2027
Importance
Level 1
#BIOGEN IDEC INC#BIIB.US#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#BIOGEN INC#BIIB#US EQUITIES